IL187522A0 - Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage - Google Patents

Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage

Info

Publication number
IL187522A0
IL187522A0 IL187522A IL18752207A IL187522A0 IL 187522 A0 IL187522 A0 IL 187522A0 IL 187522 A IL187522 A IL 187522A IL 18752207 A IL18752207 A IL 18752207A IL 187522 A0 IL187522 A0 IL 187522A0
Authority
IL
Israel
Prior art keywords
lkktet
injury
treating
damage
methods
Prior art date
Application number
IL187522A
Other languages
English (en)
Original Assignee
Regenerx Biopharmaceuticals
Goldstein Allan L
Crockford David
Finkelstein Jack Jr
Sosne Gabriel
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regenerx Biopharmaceuticals, Goldstein Allan L, Crockford David, Finkelstein Jack Jr, Sosne Gabriel filed Critical Regenerx Biopharmaceuticals
Publication of IL187522A0 publication Critical patent/IL187522A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IL187522A 2005-06-17 2007-11-20 Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage IL187522A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69126105P 2005-06-17 2005-06-17
US77694706P 2006-02-28 2006-02-28
PCT/US2006/023758 WO2006138707A1 (en) 2005-06-17 2006-06-19 Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage

Publications (1)

Publication Number Publication Date
IL187522A0 true IL187522A0 (en) 2008-03-20

Family

ID=37570786

Family Applications (4)

Application Number Title Priority Date Filing Date
IL187522A IL187522A0 (en) 2005-06-17 2007-11-20 Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage
IL187617A IL187617A0 (en) 2005-06-17 2007-11-25 Lkktet and/or lkktnt peptide compositions and methods
IL187781A IL187781A (en) 2005-06-17 2007-11-29 Use of LKKTET and / or LKKTNT peptides to treat intraocular pressure increase
IL218504A IL218504A (en) 2005-06-17 2012-03-06 Use of lkktet and / or lkktnt peptides to treat dry eye syndrome

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL187617A IL187617A0 (en) 2005-06-17 2007-11-25 Lkktet and/or lkktnt peptide compositions and methods
IL187781A IL187781A (en) 2005-06-17 2007-11-29 Use of LKKTET and / or LKKTNT peptides to treat intraocular pressure increase
IL218504A IL218504A (en) 2005-06-17 2012-03-06 Use of lkktet and / or lkktnt peptides to treat dry eye syndrome

Country Status (11)

Country Link
US (8) US20090131313A1 (https=)
EP (4) EP1904080A4 (https=)
JP (3) JP2008543877A (https=)
KR (3) KR20080021782A (https=)
CN (1) CN105106931A (https=)
AU (3) AU2006261156B2 (https=)
CA (3) CA2612410A1 (https=)
HK (1) HK1218248A1 (https=)
IL (4) IL187522A0 (https=)
MX (3) MX2007015956A (https=)
WO (3) WO2006138707A1 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011514383A (ja) * 2008-03-17 2011-05-06 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 改良されたベータチモシンフラグメント
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
WO2011044589A2 (en) * 2009-10-09 2011-04-14 Board Of Regents, The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
CA2866115C (en) 2012-03-01 2020-03-24 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides
EP2698162A1 (en) 2012-08-15 2014-02-19 Credentis AG Method for producing a composition for treating a tooth lesion
AU2014345802B2 (en) * 2013-11-07 2018-01-25 Dr. August Wolff Gmbh & Co. Kg Arzneimittel Storage stable lyophilized tripeptide formulations
WO2015138604A1 (en) 2014-03-12 2015-09-17 University Of Virginia Patent Foundation Compositions and methods for treating eye infections and disease
WO2016064078A1 (ko) 2014-10-22 2016-04-28 주식회사 지트리비앤티 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형
MA41299A (fr) * 2014-12-30 2017-11-07 Axim Biotechnologies Inc Solutions ophtalmiques pour le traitement du glaucome et de la conjonctivite
US9867868B2 (en) * 2015-08-18 2018-01-16 G-Treebnt Co., Ltd. Pharmaceutical composition for treating or preventing corneal wound comprising thymosin β4 and citric acid
KR20170021667A (ko) 2015-08-18 2017-02-28 주식회사 지트리비앤티 티모신 β4를 유효성분으로 포함하는 신경영양성각막염 치료용 조성물
KR102487614B1 (ko) 2015-10-06 2023-01-12 에이치엘비테라퓨틱스 주식회사 티모신 β4를 포함하는 안약의 제조방법
JP6889771B2 (ja) * 2016-07-18 2021-06-18 リジェンツリー リミテッド ライアビリティ カンパニー ドライアイ症候群を治療する方法
KR102115158B1 (ko) * 2016-11-29 2020-05-26 주식회사 지트리파마슈티컬 티모신 베타 4 를 함유하는 제형
BR112019017275A2 (pt) 2017-02-21 2020-05-12 Tearsolutions, Inc. Composições peptídicas estáveis
KR102340750B1 (ko) * 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제
KR101910908B1 (ko) * 2017-06-14 2018-10-24 (주)휴온스 Gly-Tβ4 (Gly-티모신β4)을 함유하는 안구건조증 치료용 약학적 조성물
US10342824B2 (en) 2017-07-17 2019-07-09 Dr. Marlowe's Weight Loss Institute, P.L.L.C. Supplement for treating side effects of medications which cause metabolic acidosis
JP2021504349A (ja) * 2017-11-24 2021-02-15 ジー−トゥリー・ビーエヌティ・カンパニー・リミテッドＧ−Ｔｒｅｅｂｎｔ Ｃｏ．， Ｌｔｄ． チモシンβ４またはその誘導体を有効成分として含む杯細胞増殖またはムチン分泌を促進するための組成物
JP2023546757A (ja) 2020-10-22 2023-11-07 シークエル・バイオ・インコーポレイテッド ペプチド製剤および眼科におけるその使用
CA3260743A1 (en) * 2022-07-01 2024-01-04 Tearsolutions, Inc. Stable peptide compositions and their methods of use for the treatment of eye symptoms related to moderate/severe dry eye

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4906613A (en) 1985-11-05 1990-03-06 Schering Corporation Antiglaucoma compositions and methods
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
FR2647675B1 (fr) 1989-06-05 1994-05-20 Sanofi Utilisation d'un derive de la statine dans le traitement des affections oculaires
US5564345A (en) * 1993-05-11 1996-10-15 Park Ohio Industries Inc. Stackable table, table assembly, and tray and table combination
ATE300936T1 (de) * 1992-05-06 2005-08-15 Alcon Lab Inc Anwendung von boral-polyol-komplexen für ophthalmische arzneizusammensetzungen
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
WO1996003158A1 (en) 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
GB9806632D0 (en) 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
AU766826B2 (en) * 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
AU2001292881A1 (en) * 2000-09-20 2002-04-02 The Regents Of The University Of California Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
AU2002255736B2 (en) * 2001-03-15 2006-08-31 Regenerx, Biopharmaceuticals, Inc. Methods of treating disorders of the eye and surrounding tissue with thymosin beta4 (Tbeta4), analogues, isoforms and other derivatives
WO2003020215A2 (en) * 2001-08-29 2003-03-13 Regenerx Biopharmaceuticals, Inc. Methods of treating mycocardial event related coditions with thymosin beta 4
US20040005644A1 (en) * 2002-02-28 2004-01-08 Su Yan A. Method and composition for detection and treatment of breast cancer
EP1542768A1 (en) * 2002-09-20 2005-06-22 Alcon, Inc. Use of cytokine synthesis inhibitors for the treatment of dry eye disorders
US20060263360A1 (en) * 2003-03-31 2006-11-23 Regenerx Biopharmaceuticals, Inc. Compositions and methods for delivering thymosin beta 4, analogues, isoforms and other derivatives
WO2004099768A1 (en) * 2003-05-05 2004-11-18 Regenerx Biopharmaceuticals, Inc. Method for detecting development of a physiological disorder in a subject
KR102632066B1 (ko) 2015-07-30 2024-02-02 가부시키가이샤 한도오따이 에네루기 켄큐쇼 발광 장치의 제작 방법, 발광 장치, 모듈, 및 전자 기기

Also Published As

Publication number Publication date
US10004785B2 (en) 2018-06-26
US20170128540A1 (en) 2017-05-11
KR20080021782A (ko) 2008-03-07
MX2007015956A (es) 2008-03-06
WO2006138708A1 (en) 2006-12-28
MX2007015957A (es) 2008-03-06
WO2006138709A2 (en) 2006-12-28
JP2008543879A (ja) 2008-12-04
AU2006261156A1 (en) 2006-12-28
IL218504A (en) 2013-10-31
CN105106931A (zh) 2015-12-02
EP1896050A4 (en) 2010-01-27
EP3326647A1 (en) 2018-05-30
JP2008543878A (ja) 2008-12-04
HK1218248A1 (zh) 2017-02-10
CA2612410A1 (en) 2006-12-28
CA2612405A1 (en) 2006-12-28
US20160193301A1 (en) 2016-07-07
AU2006261157A1 (en) 2006-12-28
US9585941B2 (en) 2017-03-07
US20120071411A1 (en) 2012-03-22
US9821030B2 (en) 2017-11-21
US20180028619A1 (en) 2018-02-01
IL187781A (en) 2012-04-30
EP1904080A1 (en) 2008-04-02
US20080214456A1 (en) 2008-09-04
EP1906986A1 (en) 2008-04-09
JP2008543877A (ja) 2008-12-04
US20090118196A1 (en) 2009-05-07
AU2006261156B2 (en) 2012-05-31
EP1906986A4 (en) 2011-02-23
MX2007015958A (es) 2008-04-17
IL187617A0 (en) 2008-03-20
KR20080033939A (ko) 2008-04-17
IL187781A0 (en) 2008-08-07
US20160287673A1 (en) 2016-10-06
US8383576B2 (en) 2013-02-26
WO2006138708B1 (en) 2007-04-05
WO2006138707A1 (en) 2006-12-28
IL218504A0 (en) 2012-04-30
EP1896050A2 (en) 2008-03-12
US20090131313A1 (en) 2009-05-21
WO2006138709A3 (en) 2007-07-05
CA2612522A1 (en) 2006-12-28
KR20080018268A (ko) 2008-02-27
EP1904080A4 (en) 2011-02-16
AU2006261155A1 (en) 2006-12-28

Similar Documents

Publication Publication Date Title
IL187522A0 (en) Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage
EP1959929A4 (en) COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL SUFFERING
PT3006040T (pt) Métodos e composições para o tratamento de neuropatias
IL180844A0 (en) Compositions and methods for treating excessive bleeding
IL185056A0 (en) Compositions and methods for treating or preventing flaviviridae infections
SI1771201T1 (sl) Sestavki in metode za zdravljenje ali preprečevanje z oksalatom-povezanih bolezni
IL186963A0 (en) Methods and compositions for treating pain
PL1965816T3 (pl) Kompozycje farmaceutyczne i sposoby leczenia lub zapobiegania chorobom związanym ze szczawianami
IL185540A0 (en) Compositions and methods for treating acne
ZA200708575B (en) Methods and compositions for treating or preventing cancer
PL1761266T3 (pl) Związki, preparaty i sposoby leczenia lub zapobiegania procesom zapalnym skóry
WO2010059245A3 (en) Compositions and methods for treating or preventing radiation injury
IL230935A0 (en) Formulations and methods for treating amyloidosis
ZA200805419B (en) Compositions and methods for preventing or treating inflammatory bowel disease
EP1890712A4 (en) COMPOSITIONS AND METHODS FOR TREATING PAIN
EP1868435A4 (en) COMBINATIONS, METHODS AND COMPOSITIONS FOR TREATING CANCER
GB0718918D0 (en) Compositions and methods for treating skin conditions
IL173868A0 (en) Rage-related methods and compositions for treating glomerular injury
SI2056799T1 (sl) Sestavki in postopki za zdravljenje ali preprečevanje glavkoma ali njegovega napredovanja
EP1933853A4 (en) TREATMENT OF TISSUE DISTRACTION AND COMPOSITION FOR APPLYING THEREOF
EP1959982A4 (en) METHODS AND COMPOSITIONS FOR PREVENTING AND / OR TREATING PANCREATITIS
HK1114336A (en) Lkktet and/or lkktnt compositions and methods for treating or preventing tissue deterioration, injury or damage
GB0519334D0 (en) Method and composition for treating skin
IL187889A0 (en) Compositions and methods for preventing or treating hiv infection
PT1965816T (pt) Composições farmacêuticas e métodos de tratamento ou prevenção de uma doença associada a oxalato